Otezla is a medicine used to treat adults with: - moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in patients who have not responded to or cannot use other systemic (affecting the whole body) treatments for psoriasis, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen’ before being exposed to ultraviolet light; - active psoriatic arthritis (inflammation of the joints associated with psoriasis) in patients who cannot take or have not responded well enough to other treatments called disease-modifying antirheumatic drugs (DMARDs). Otezla may be used alone or combined with other DMARDs; - ulcers in the mouth caused by Behçet’s disease, an inflammatory disease that may affect many parts of the body. Otezla is also used to treat children aged 6 years and older weighing at least 20 kg with moderate to severe plaque psoriasis who can receive systemic treatments. Otezla contains the active substance apremilast.
Therapeutic Indication
### Therapeutic indication **Psoriatic arthritis** Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. **Psoriasis** Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis (PSOR) in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). **Paediatric psoriasis** Otezla is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years and weighing at least 20 kg who are candidates for systemic therapy. **Behçet’s disease** Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L04AA32
ATC Item
apremilast
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| apremilast | N/A | 阿普米司特 |
EMA Name
Otezla
Medicine Name
Otezla
Aliases
N/A
